D-dimer testing plays an important role in the assessment of suspected thrombotic conditions and is increasingly incorporated into modern coagulation testing portfolios. Laboratories are seeking automated and reliable approaches for processing these assays. Continued emphasis on rapid diagnostic decision-making is expected to support demand for D-dimer testing.

The Global Coagulation Market is undergoing significant transformation as healthcare systems increasingly prioritize faster diagnosis, laboratory automation, specialized testing, and more precise management of bleeding and thrombotic disorders.

According to The Insight Partners, the Global Coagulation Market is expected to grow from US$6,295.28 million in 2022 to US$10,853.28 million by 2030, registering a CAGR of 7.0% from 2022 to 2030.

The market is being shaped by several converging trends, including the adoption of automated coagulation analyzers, growing demand for point-of-care testing, advances in anticoagulant monitoring, and the development of emerging technologies for more comprehensive assessment of hemostasis.

Recent developments from diagnostic companies, regulators, and research institutions indicate that coagulation testing is moving beyond conventional laboratory workflows. Automation and digital connectivity are becoming increasingly important, while specialized assays and emerging precision technologies are creating new opportunities across clinical laboratories and healthcare settings.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00030085

Automation Is Transforming the Coagulation Market

Laboratory automation has become one of the most important trends shaping the coagulation market.

Hospitals and diagnostic laboratories are processing growing numbers of samples while facing pressure to improve turnaround times, reduce manual intervention, and maintain consistent testing quality. Automated coagulation analyzers can address some of these requirements by supporting continuous sample processing, automated reruns, reflex testing, quality checks, and integration with laboratory information systems.

A notable development came from Sysmex, which introduced the CN-9000 Automated Hemostasis Solution in 2026. The system is designed for high-volume laboratories and incorporates features such as continuous sample loading, automated rerun and reflex testing, and sample-integrity checks. Sysmex reports throughput of up to 1,000 samples per hour.

This development illustrates the direction of the industry. Coagulation testing is increasingly being incorporated into automated laboratory workflows rather than functioning as an isolated testing process.

Point-of-Care Coagulation Testing Is Gaining Importance

Another important trend is the growing role of point-of-care coagulation testing.

Conventional laboratory testing may involve sample collection, transportation, processing, and analysis before results reach clinicians. Point-of-care technologies can provide selected coagulation results closer to the patient, which may be particularly valuable when treatment decisions need to be made quickly.

Applications include emergency care, surgery, intensive care, and anticoagulation management. INR testing is one established example, particularly for patients receiving vitamin K antagonist therapy.

The opportunity extends beyond speed. Point-of-care coagulation technologies must also provide appropriate analytical performance, ease of use, quality control, connectivity, and clinical reliability.

As healthcare providers increasingly explore decentralized diagnostics, these factors will influence adoption of point-of-care coagulation systems.

Specialized Coagulation Testing Is Expanding

Routine tests such as prothrombin time (PT) and activated partial thromboplastin time (aPTT) remain essential components of coagulation diagnostics. However, modern clinical practice increasingly requires more specialized information.

Recent FDA records demonstrate this expansion, with 2026 regulatory records covering coagulation testing applications involving anti-Xa testing, apixaban testing, lupus anticoagulant testing, and factor VIII chromogenic assays.

Anti-Xa testing is particularly relevant to anticoagulant management because healthcare providers may need to assess the activity of heparin or certain factor Xa inhibitors in specific clinical situations.

This increasing demand for specialized testing creates opportunities for companies developing analyzers, reagents, calibrators, quality-control materials, and software platforms that support broader coagulation testing menus.

Thrombin Generation Testing Represents an Emerging Opportunity

Thrombin generation testing (TGT) is another technology attracting attention within the coagulation diagnostics field.

Conventional coagulation tests generally evaluate particular stages or components of the clotting process. Thrombin generation assays attempt to provide a broader picture of the body’s ability to generate thrombin, which plays a central role in clot formation.

A 2026 review published in Clinics in Laboratory Medicine examined potential applications of thrombin generation assays in assessing bleeding and thrombotic risk and monitoring treatment.

However, TGT remains an emerging technology. Wider adoption will require continued clinical validation, standardization, reproducibility, and clear evidence of how test results should influence clinical decisions.

Therefore, thrombin generation should currently be viewed as a developing opportunity rather than a replacement for established coagulation assays.

Precision Diagnostics Could Reshape Hemostasis Testing

The broader movement toward precision medicine is also influencing coagulation diagnostics.

In 2026, researchers reported analytical validation of a multiplex mass-spectrometry-based test for five coagulation factors. Such technologies could provide laboratories with more detailed information about specific coagulation abnormalities and potentially support more targeted diagnostic approaches.

Another area of innovation is reducing the volume of blood required for testing.

A 2026 study investigated an ultra-low-volume thromboelastometry approach using approximately 4–6 microliters of blood in the research setting. The technology demonstrated the ability to identify coagulation abnormalities within several minutes under the study conditions.

If these approaches achieve broader clinical validation and regulatory acceptance, low-volume coagulation testing could have applications in pediatric care, critical care, and decentralized testing environments.

Hemophilia Treatment Is Creating New Diagnostic Requirements

Innovation in the treatment of bleeding disorders is also influencing the coagulation market.

Hemophilia management increasingly involves advanced therapies and more individualized treatment strategies. As therapeutic approaches evolve, laboratories may require specialized testing to evaluate coagulation factors, inhibitors, and treatment response.

A recent European regulatory development illustrates this trend. In September 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Frehemgo (denecimig) for routine prophylaxis of bleeding episodes in eligible patients with hemophilia A.

Developments such as these can increase the importance of specialized coagulation diagnostics because treatment innovation and laboratory monitoring often evolve alongside one another.

Competitive Landscape

The coagulation market includes established diagnostic and medical technology companies such as F. Hoffmann-La Roche Ltd, Sysmex Corporation, HORIBA Ltd, Helena Laboratories Corporation, Diagnostica Stago, Inc., Siemens Healthineers AG, Nordic Biomarker AB, ImproGen Diagnostik Kimya San. & Tic. Ltd. Şti., Genrui Biotech Co., Ltd., and Transasia Bio-Medicals Ltd.

These companies participate across different areas of the coagulation diagnostics ecosystem, including analyzers, reagents, assays, automation, and laboratory solutions.

The growing emphasis on automation, specialized testing, connectivity, and workflow efficiency is likely to make technological differentiation increasingly important. Companies that can integrate multiple testing capabilities into efficient laboratory workflows may be better positioned to address the changing requirements of hospitals and diagnostic laboratories.

Future Outlook

The future of the coagulation market is likely to be defined by the convergence of automation, specialized diagnostics, connectivity, and precision testing.

High-throughput laboratories are expected to continue investing in automated coagulation analyzers as they seek to manage increasing workloads while maintaining consistent testing processes. Integration with laboratory information systems and broader automation platforms may become increasingly important as laboratories pursue more connected workflows.

Point-of-care testing is also expected to remain an important area of development, particularly where rapid coagulation information can support time-sensitive clinical decisions. The challenge will be ensuring that decentralized testing maintains appropriate quality and analytical standards.

Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish

Related Reports:

Livestock Monitoring System Market Trends, Size & Forecast by 2034

In-Vitro Diagnostic Instruments Market Demand, Trends & Forecast by 2034

About Us

The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.

Contact US

Contact Person: Ankit Mathur

Phone: +1-646-491-9876

E-mail : sales@theinsightpartners.com